We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

MaxCyte Inc (MXCT) Ord USD0.01 (DI)

Sell:310.00p Buy:330.00p 0 Change: 3.00p (0.93%)
FTSE AIM 100:0.23%
Market closed |  Prices as at close on 24 April 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:310.00p
Buy:330.00p
Change: 3.00p (0.93%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 24 April 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:310.00p
Buy:330.00p
Change: 3.00p (0.93%)
Market closed |  Prices as at close on 24 April 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

MaxCyte, Inc. is a commercial cell engineering company. The Company is focused on providing enabling platform technologies to advance cell-based research and development, as well as next-generation cell therapeutic discovery, development and commercialization. The Company has developed and commercialized its Flow Electroporation platform, which facilitates complex engineering of a variety of cells. Its ExPERT platform is based on its Flow Electroporation technology, which has been designed to address the cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. Its ExPERT platform consists of three instruments, which are known as the ATx, STx and GTx. The Company has also developed CARMA, a therapeutic platform based on transfecting mRNA into unstimulated cells for the development of immune cell therapies.

Contact details

Address:
22 FIRSTFIELD ROAD, SUITE 250
GAITHERSBURG
20878
United States
Telephone:
+1 (0301) 5175556
Website:
https://www.maxcyte.com/

Important dates

Future events
Quarterly results 07 May 2024 07/05/24
Past events
Final results 13 March 2024 13/03/24
Quarter 3 results 09 November 2023 09/11/23
Interim results 10 August 2023 10/08/23
Annual report 21 June 2023 21/06/23
Quarterly results 11 May 2023 11/05/23

General stock information

EPIC:
MXCT
ISIN:
US57777K1060
Market cap:
£333.21 million
Shares in issue:
104.13 million
Sector:
Pharmaceuticals & Biotechnology
Exchange:
London Stock Exchange
Currency:
Sterling pence
Indices:
FTSE AIM 100,FTSE AIM All Share

Key personnel

  • Douglas Doerfler
    President, Chief Executive Officer, Director
  • Ronald Holtz
    Interim Chief Financial Officer
  • Maher Masoud
    Executive Vice President, General Counsel
  • Thomas Ross
    Executive Vice President, Global Sales and Marketing
  • Cenk Sumen
    Chief Scientific Officer
  • James Brady
    Vice President - Technical Applications and Customer Support
  • Kevin Gutshall
    Vice President, Corporate Business Development
  • Steve Nardi
    Vice President, Manufacturing and Engineering Operations
  • Kathryn Wekselman
    Vice President - Regulatory
  • Sarah Meeks
    Vice President - Business Development

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by NBTrader.
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.